ImmunityBio Reports Record Q1 Revenue Tripling Year-Over-Year Driven by Anktiva
Zoetis reported lower-than-expected first-quarter 2026 results driven by U.S. headwinds and lowered its financial guidance. Separately, ImmunityBio shares dropped 11.46 percent despite record revenue growth from its cancer drug Anktiva.
insidermonkey.comImmunityBio Inc. reported record first-quarter revenue of $21.07 million, more than tripling from $7 million in the year-ago period, driven by increased net trade sales of Anktiva. The company also posted a 168 percent increase in Anktiva unit sales volume, reflecting ongoing commercial activities for the bladder cancer treatment.
The biotechnology company reported a first-quarter GAAP loss of 62 cents per share, wider than the consensus estimate of a 7 cent loss. On an adjusted basis, ImmunityBio reported a loss of 8 cents per share. In response to the performance, the company lowered its full-year 2026 financial guidance.
ImmunityBio positioned the Anktiva momentum as a bright spot. The revenue surge and unit sales growth came even as the per-share loss remained wider than anticipated. Zoetis separately reported Q1 2026 earnings that fell short of Wall Street forecasts for the three months ended March 31 and cut its outlook for the remainder of 2026, with its stock falling in response.
The results for both companies highlighted performance across the health care sector in the opening months of 2026. ImmunityBio exceeded sales expectations.
Transparency
Mostly clean rewrite focused on verifiable financial metrics; minor inherited framing around loss severity and guidance cut.
Valence skew: negative valence repeatedly attached to earnings miss
The same facts could be read as strong validation of ImmunityBio's commercial execution, with Anktiva demonstrating robust demand through record revenue growth and unit sales nearly tripling year-over-year.
2 independent outlets report the same core facts. This score blends how many outlets corroborate, their editorial tier, and how closely their facts agree — it measures corroboration, not proof.
Sources framed at 65 → our rewrite 18. We stripped 47 points of framing the sources carried in.
Story details
Related Stories
Substrate placeholder — needs reviewIran Suspends Indirect Talks With U.S. Amid Escalating Israel-Hezbollah Conflict in Lebanon
Iran has stopped all message exchange with the United States, including ongoing talks, in response to Israel's expanded offensive in Lebanon. The suspension was reported by Tasnim News Agency, which is affiliated with the Islamic Revolutionary Guard Corps according to the Jerusal…
france24.comIranian Official: Tehran Manages Strait of Hormuz and Will Not Allow Maritime Blockade
Mohsen Rezaei stated that Iran controls the Strait of Hormuz and will not allow a maritime blockade to continue. Oil prices rose 8 percent on the day of the statements.
Al JazeeraGreece Reviews Asylum Status for Syrians and Afghans After Conflicts End
Greek authorities began reviewing protection status for Syrians and Afghans in February after the end of Syria's civil war and the 2021 Taliban takeover. The reviews target men and coincide with new returns legislation.